Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms
World Journal of Stem Cells · 26.07.2026 · 18 (7)
DOI: 10.4252/wjsc.120363 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Stem Cells, online erschienen am 26.07.2026. Verfasst von Sara Akhtar Khan und 9 weiteren Autor:innen. Die Arbeit nennt 197 Literaturangaben.
Abstract (Originalsprache)
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have become potential next-generation drug delivery systems that combine the biological effectiveness of cell-based therapies with the reliability and controllability of acellular approaches. MSC-EVs are nanoscale vesicles enclosed by membranes that can carry proteins, lipids and nucleic acids, facilitating directed intercellular communication and therapeutic regulation. This review offers an extensive summary of the biological foundation of MSC-EVs, their advantages compared to traditional nanocarriers and the mechanisms that regulate targeted delivery to diseased microenvironments. We methodically examine present methods for therapeutic cargo loading, encompassing both passive and active techniques, genetic and biogenic modifications of parental mesenchymal stem cells, along with surface functionalization. Recent developments in hybrid and stimuli-responsive extracellular vesicle platforms that improve stability, targeting accuracy, and controlled release are also emphasized. Additionally, we outline preclinical and upcoming clinical uses of MSC-EVs in cancer, cardiovascular, ischemic and various other diseased conditions. Ultimately, we thoroughly assess the translational hurdles associated with large-scale production, standardization, storage, safety and regulatory processes while highlighting prospects for upcoming clinical advancements. In summary, this review highlights the transformative capability of MSC-EVs as adaptable and biologically smart drug delivery systems, while emphasizing the need for aligned technological, regulatory and clinical progress to facilitate their effective conversion into authorized therapies.
Zitieren
APA
Khan, S. A., Jha, S. K., Tiwari, P., Narang, J., Gupta, V., Singh, S. K., Anand, K., Rajendran, R. L., Gangadaran, P., & Parvez, S. (2026). Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms. World Journal of Stem Cells, 18(7). https://doi.org/10.4252/wjsc.120363
Vancouver
Khan SA, Jha SK, Tiwari P, Narang J, Gupta V, Singh SK, et al. Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms. World Journal of Stem Cells. 2026;18(7). doi:10.4252/wjsc.120363
BibTeX
@article{Khan2026,
author = {Khan, Sara Akhtar and Jha, Saurabh Kumar and Tiwari, Prachi and Narang, Jagriti and Gupta, Vinamre and Singh, Sachin Kumar and Anand, Kushi and Rajendran, Ramya Lakshmi and Gangadaran, Prakash and Parvez, Suhel},
title = {Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms},
journal = {World Journal of Stem Cells},
year = {2026},
volume = {18},
number = {7},
doi = {10.4252/wjsc.120363}
}
EUVIMED